Med. Pro Praxi 2008; 5(9): 310-312

Farmakologická prevence chronického srdečního selhání

MUDr. Filip Málek
Kardiocentrum FN Královské Vinohrady, III. lékařská fakulta Univerzity Karlovy, Praha

Farmakologická prevence chronického srdečního selhání zahrnuje terapii stavů a onemocnění spojených s vysokým rizikem vzniku strukturálního srdečního poškození a následného rozvoje srdečního selhání. Primární prevence srdečního selhání se týká především nemocných s arteriální hypertenzí a/nebo s ischemickou chorobou srdeční. Dále rozvoji srdečního selhání brání podle současných poznatků léčba nemocných se srdečním onemocněním ve stadiu asymptomatické srdeční dysfunkce. Důkazy máme pro léčbu inhibitory angiotenzin-konvertujícího enzymu u pacientů se srdeční dysfunkcí různé etiologie a pro betablokátory u pacientů po infarktu myokardu. Agresivní terapie nemocných se symptomatickou srdeční dysfunkcí brání pak podle medicíny založené na důkazech rozvoji pokročilého stadia srdečního selhání a snižuje riziko úmrtí na náhlou srdeční smrt a úmrtí na progresi srdečního selhání.

Keywords: farmakoterapie, prevence, srdeční dysfunkce, chronické srdeční selhání

Published: December 19, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Farmakologická prevence chronického srdečního selhání. Med. praxi. 2008;5(9):310-312.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Conroy R, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. Go to original source... Go to PubMed...
    2. Dahlof B, Deveraux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995-1003. Go to original source... Go to PubMed...
    3. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovasclar Disease Prevention in Clinical Practice. Eur Heart J 2007; 28: 2375-2414.
    4. Granger BB, Swedberg K, Ekman I, Granger CB, Olofsson B, McMurray JJ, Yusuf S, Michelson EL, Pfeffer MA, CHARM investigators. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005; 366(9502): 2005-2011. Go to original source... Go to PubMed...
    5. Guidelines for the Management of Arterial Hypertension 2007. Journal of Hypertension 2007; 25: 1105-1187. Go to original source... Go to PubMed...
    6. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guidelines update for the diagnosis and management of chronic heart failure in the adult. Task Force on Practice Guidelines. Circulation 2005; 112: 1825-1852. Go to original source...
    7. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3: 249-254. Go to original source... Go to PubMed...
    8. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. Diuretic: The Antihyperensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
    9. Mosterd A, Hoes AW, deBruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population. Eur Heart J 1999; 20: 447-455. Go to original source... Go to PubMed...
    10. Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. Go to original source... Go to PubMed...
    11. Špinar J, Hradec J, Meluzín J, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2006 Cor Vasa 2007; 49(11): 75-104.
    12. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390. Go to original source... Go to PubMed...
    13. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005; 26: 1115-1140. Go to original source... Go to PubMed...
    14. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-disegned overviews of randomized trials. Lancet 2003; 362: 1527-1535. Go to original source... Go to PubMed...
    15. Widimský J a kol. Srdeční selhání. Praha: Triton, 2001: 289-292.
    16. Wilhelmsen L, Rosengren A, Eriksson H, et al. Heart failure in the general population of men - morbidity, risk factors and prognosis. J Intern Med 2001; 249: 253-261. Go to original source... Go to PubMed...
    17. Williams B, Poulter NR, Brown MJ, et al. The BHS Guidelines Working Party. British Hypertension Society Guidelines for Hypertension Management, 2004 - BHS IV: Summary. BMJ 2004; 328: 634-640. Go to original source... Go to PubMed...
    18. Yusuf S, Sleight P, Pogue J, et al.Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153. Go to original source... Go to PubMed...
    19. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.